Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic
testing may help predict how cancer will respond to treatment and allow doctors to plan more
I. To develop a mechanism to collect and distribute tumor specimens to various
investigators, and a system to prioritize and develop quality-control measures for central
data reporting of studies undertaken.
II. To determine the prognostic significance of translocation subtype in Ewing sarcoma; to
determine the prognostic significance of translocation negative Ewing sarcoma.
III. To determine the prognostic significance of MRD detection in bone marrow specimens by
RT-PCR determination of EWS-ETS fusion genes.
IV. To determine whether serum levels of IGF1, IGFBP3 are of significance in the outcome of
patients with Ewing sarcoma.
V. To determine whether RNA expression profiles performed on diagnostic specimens will allow
for the identification of newer prognostic categories and potentially new molecular targets
for treatment in Ewing sarcoma.
VI. To identify new treatment targets for therapy. Further testing of these potential
targets will be carried out in hopes of expediting translation of these findings to the
VII. To establish a bank of Ewing sarcoma xenografts in SCID/Beige mice. VIII. To establish
clinical proteomics as a resource for investigations of altered signaling molecules in the
pathogenesis of Ewing sarcoma.
OUTLINE: This is a multicenter study.
Patients undergo various specimen collections, including bone marrow aspirate,
paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens.
These specimens are collected before, during, and after any chemotherapy regimens, during
follow-up, and at time of recurrence. Translocation studies are performed on specimens to
identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined.
Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase
- Newly diagnosed or recurrent Ewing's sarcoma
- Availability of the following specimens:
- Paraffin-embedded block or 20 unstained slides and 1-3 thick (50 micron)
sections from initial biopsy
- Pretreatment serum and whole blood
- Concurrent therapy is not required